Dr Nigel Irwin holds a BSc Hons in Biomedical Sciences from Ulster University (2001) and a PhD in Experimental Therapeutics for Diabetes also from Ulster (2004). He also has a Diploma in Industrial Studies (2001) and is a Fellow of HEA (2008).
Nigel began his research career in diabetes during his time as a Research Assistant in Diabetes/Electrophysiology, at University of Nevada, Reno (2000-2001). This was followed by appointment at Ulster as a Research Associate (2004-2007) and a Research Fellow (2007-2009) in Diabetes. He then became a Lecturer in Pharmacology (2009-2014) and Senior Lecturer in 2014.
He has almost 20 years experience in diabetes research with specific expertise in exploitation of gut-derived peptides for the treatment of diabetes and related disorders. His recent research has been integral in deciphering the link between diabetes and increased bone fracture risk.
Nigel is holder of several families of patents, is the recipient of research awards, and a member of healthcare science advisory boards as well as engaging in consultant activity.
He is also a member of several professional societies/committees and holds editorial roles for various respected Journals.
|Targeted exendin/apelin hybrid peptides for diabetes and obesity therapy. Funded PhD Opportunity||Friday 7 February 2020||View Details|
|Utility of combined GLP-1 and neurotensin receptor signalling, and/or related hybrid peptides, for type 2 diabetes therapy Self-funded PhD Opportunity||Tuesday 1 September 2020||View Details|
|Modulation of pancreatic beta-cell Neuropeptide Y (NPY) receptors as a novel therapeutic option for diabetes Funded PhD Opportunity||Friday 7 February 2020||View Details|